Insider Insights
24.05.2022
Preliminary analysis of reformed early access

The High Authority for Health (HAS) and National Agency for Drug Safety (ANSM) have published a prel...

Read more
Insider Insights
20.05.2022
Improving market access for new drugs

With respects to pricing and reimbursement, the societies reportedly call for the criteria that led ...

Read more
Insider Insights
19.05.2022
AstraZenecas Imfinzi approved for routine NHS use

Durvalumab was previously made available to NHS patients in 2019 through the Cancer Drugs Fund (CDF)...

Read more
Insider Insights
18.05.2022
Access to new treatments could extend lives

The research looks at the benefits for 13 medicines across four treatment areas.

Read more
Articles
17.05.2022
Is NRDL inclusion in China really the golden ticke...

Introduction As the most populous country in the world with 1.4 billion inhabitants, China has the p...

Read more
Insider Insights
04.05.2022
UK second lowest across major health outcomes

The data is derived from the Organisation for Economic Co-operation and Development (OECD) Health St...

Read more
Insider Insights
04.05.2022
CNAM spending on medicines 11.1% in 2022

Spending by the main health insurance fund (Caisse nationale d’assurance maladie, CNAM) on medicin...

Read more
04.05.2022
PMA Insights: Week 18

A short, 60 seconds read that summarises 4 handpicked articles that are worth reading about: Regulat...

Read more
Insider Insights
29.04.2022
EUCOPE anticipates OMP Regulation review

EUCOPE notes that “while these proposals don’t necessarily represent the final options included ...

Read more
Insider Insights
27.04.2022
Optimised NICE recommendations

According to the ABPI, over the last 20 years, 82% of technology appraisal recommendations have been...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.